Major advances in cellular biology, genetics, pharmacology and immunology in the past decade are beginning to be translated into progress in cancer treatment. This progress is manifested by new cytotoxic drugs which have recently entered clinical practice (taxanes, topoisomerase I inhibitors, gemcitabine, vinorelbine, new purines), as well as the efficacy of monoclonal antibody therapies against the CD-20 antigen of B-cell lymphomas and the Her2/neu oncogene in breast cancer. Several new drugs in development are targeted at reversal or prevention of the multidrug resistance mechanism caused by expression of the MDR\ gene (Pglycoprotein). Tumour angiogenesis as a target is being studied in several early clinical trials. As with many other biological therapies, the evaluation of these compounds and their integration with standard therapies presents a major challenge to clinical investigators. The emerging field of genomics and gene expression microarrays will provide enormous information about the biology of cancers. This technology offers great opportunities for the discovery of new therapeutic targets, which should provide a basis for the design and evaluation of many new agents in the coming decade.
Introduction
The past decade has seen enormous advances in our understanding of the basic biology of cancer. These include knowledge of cancer genetics, in particular of oncogenes and tumour suppressor genes, the processes of cancer cell metastasis and angiogenesis, and tumour immunology. These advances present great opportunities and challenges in many areas of oncology.
New cytotoxic agents
As shown in Table 1 , the 1990s was a very productive decade for the development of new cytotoxic anticancer drugs [1, 2] . Three new purines (fludarabine, cladribine, and pentostatin) were introduced for hematological malignancies [3] [4] [5] [6] . The new pyrimidine analogue gemcitabine has shown a broad spectrum of clinical antitumour activity, in addition to its initial approved indication in pancreatic carcinoma [7] . Capecitabine as an oral prodrug of 5-fluorouracil (5-FU) has shown significant activity in breast cancer [8, 9] . Raltitrexed is the first of a series of new agents targeted primarily at thymidylate synthase [10] . Oral therapy with modulators of 5-FU metabolism or activity will continue to be a focus of development, including the potent inhibitor of dihydropyrimidine dehydrogenase eniluracil with 5-FU and the combination of tegafur/uracil/5-FU/leucovorin [11] .
Platinum drugs have shown important curative and palliative activity in many cancers, and several analogues are currently in clinical development, notably oxaliplatin, identified as a major new agent against colorectal cancer [12] . The taxanes, paclitaxel and docetaxel, are continuing to be studied in a wide range of tumours [13, 14] . The topoisomerase I inhibitors represent a new class of agents notable for the activity of irinotecan in colorectal cancers, and topotecan in refractory ovarian cancers [15] [16] [17] [18] . Many of these new drugs, as well as the Vinca alkaloid vinorelbine, are active in lung cancers, and their roles in combination with platinum drugs in particular will be a focus of intense clinical research for the next several years [19, 20] .
Agents for supportive care, palliation, and chemoprotection
Any discussion of new cancer therapies developed in the 1990s should include mention of a range of new drugs which increase the quality of life and safety margin for patients on chemotherapy, Table 2 . Hematopoietic growth factors have reduced the risk of infectious and hemorrhagic complications of cytotoxic therapies [21] . An ongoing debate is the cost efficacy and appropriate use of these agents, since their cumulative costs far exceed the total expenses of all chemotherapy drugs for health insurance systems in the U.S. and Western Europe. The 5-HT3 serotonin antagonists have greatly ameliorated the problem of chemotherapy-induced nausea, again leading to dilemmas and guidelines for the use of these sometimes expensive new agents for various degrees of emetogenic potential of therapies [22] . Transdermal fentanyl is a significant advance in the armamentarium against cancer-related pain [23] . The bisphosphonates, notably pamidronate, have been useful not only in alleviating hypercalcemia but also in altering the clinical course of osteolytic metastases in multiple myeloma, and may have a role in the treatment of bone metastases of other types of cancer [24] . Finally, agents have been introduced which protect against non-hematological toxicities, such as dexrazoxane for the cardiac toxicity of anthracyclines and amifostine for the nephrotoxicity of cisplatin [25] . The appropriate use of these various agents will continue to be the topics of both clinical investigation and debate among health care providers.
Inhibitors of multidrug resistance
Perhaps the best understood mechanism of cellular resistance to therapies is the form of multidrug resistance (MDR) caused by expression of the multidrug transporter, P-glycoprotein (P-gp), and encoded by the MDR\ gene [26] . The rationale for P-gp as a target for therapy is based on almost two decades of preclinical and clinical research [27, 28] . P-glycoprotein expression is an adverse prognostic factor when it is present at diagnosis in many types of tumours, including several forms of leukemia and lymphoma, retinoblastoma, neuroblastoma, soft tissue sarcomas in children, osteosarcomas, breast cancer and ovarian cancer. MDR has been shown to be reversible in tissue culture and animal models using various inhibitors of the P-gp transporter. Reversal of clinical resistance using some of these agents has also been demonstrated in Phase I and II clinical trials. Finally, this MDR mechanism can be prevented from emerging in drug resistant subclone by treating cancer cell populations concurrently with MDR-related cytotoxins and inhibitors of P-gp [29] . The current status of drugs in development as inhibitors or modulators of P-glycoprotein MDR is listed in Table 3 . Valspodar is the agent in the most advanced stage of development, with Phase III trials ongoing in acute myeloid leukemias, multiple myeloma, and ovarian carcinoma. The major factor potentially limiting the efficacy of these agents is the complexity and multiplicity of cellular resistance mechanisms to anticancer drugs. More knowledge of the nature and expression of these mechanisms in human cancers should be a high research priority. Drug interactions related to inhibition of P-gp, as well as of other transporters and cytochrome P-450 CYP3A4, complicate the design and interpretation of clinical trials of modulation of MDR [27, 28] .
In addition to reversal or prevention of MDR, inhibitors of P-gp may have a major role in enhancing the oral bioavailability of MDR-related cytotoxins and other drugs. The role of P-gp in limiting drug absorption has been well demonstrated in knockout mouse models [30] . Both preclinical and clinical data support the concept that agents such as paclitaxel can be administered orally in combination with P-gp modulators, an approach which may be less toxic and more cost-effective for patients [31] [32] [33] .
Monoclonal antibodies
The promise of monoclonal antibodies as cancer therapies is finally being fulfilled, after almost two decades of clinical trials [34] . The anti-CD20 antibody rituximab (Rituxan™) has produced a 48% remission rate in a pivotal phase II trial in low-grade B-cell lymphomas, with remissions lasting approximately a year [35] [36] [37] . Trials of rituximab in combination with chemotherapy are in progress. At the same time, the anti-HER2/neu antibody trastuzumab (Herceptin™) has demonstrated efficacy both as a single agent and in combination with chemotherapy in women with advanced breast cancer [38, 39] . The apparent synergistic antitumour effect of trastuzumab with paclitaxel, its exacerbation of the cardiotoxicity of doxorubicin, and its role in adjuvant therapies are the subjects of current research. Several other monoclonal antibodies and radioisotopic conjugates with monoclonal antibodies are currently in various stages of investigation [34] .
Angiogenesis as a target for cancer therapy
Angiogenesis, or the formation of new blood vessels, has long been identified as an important aspect of cancer growth and a potential target for cancer therapies [40] [41] [42] [43] [44] [45] . A large number of new drugs which have demonstrated antiangiogenic properties in preclinical models are now in various phases of clinical trials, as shown in Table 4 . These drugs include several inhibitors of matrix metalloproteinases, antibodies and drugs which inhibit vascular endothelial growth factor (VEGF) or its receptor, and agents which are directly toxic to endothelial cells. Major challenges for clinical investigators developing these agents include the design of suitable endpoints for monitoring efficacy in a class of agents that may result in stabilization rather than regression of tumour growth, the identification of surrogate markers of drug action, and the integration of these agents with standard chemotherapy regimens.
Oncogene targeted agents, gene therapies, and gene expression microarrays
Knowledge about the molecular basis for oncogenesis is being translated into novel therapies which are in early stages of clinical development. Several companies are developing small molecule inhibitors of farnesyl transferase inhibitors, an enzyme which is essential for the proper anchoring and function of the ras oncogene in the cell membrane [46] . The identification of mutations in the p53 gene in the majority of human cancers has led to a variety of approaches, including re-introduction of a normal p53 using gene therapy vectors [47] , as well as the use of a defective adenovirus which selectively replicates in and kills cells with mutant p53 [48] .
Other gene therapy methods depend upon the transfection into tumour cells of microbial genes for enzymes which activate prodrugs, such as the herpes simplex thymidine kinase gene with gancyclovir [49] , or the cytosine deaminase gene with fluorocytosine [50] . An inherent liability with these gene therapy approaches is the localised nature of the treatment, involving injections of cells or vectors directly into large, visible tumours. Unfortunately, this does not address the problem of system micrometastases, which limits the survival of most patients who die of cancers. One of the foremost advances of the last half of thi s decade has been the ability to profile the expression of thousands of genes by microarrays [51] [52] [53] . These new gene chip technologies are likely to revolutionize our understanding of cancer mechanisms, cellular responses to therapies, and predictions of genetic predispositions and outcomes.
